AT217045B - Process for the preparation of new monoalkylated or monohalogenated N-derivatives of 10,11-dihydro-5H-dibenzo [b, f] azepines and 5H-dibenzo [b, f] azepines - Google Patents
Process for the preparation of new monoalkylated or monohalogenated N-derivatives of 10,11-dihydro-5H-dibenzo [b, f] azepines and 5H-dibenzo [b, f] azepinesInfo
- Publication number
- AT217045B AT217045B AT567460A AT567460A AT217045B AT 217045 B AT217045 B AT 217045B AT 567460 A AT567460 A AT 567460A AT 567460 A AT567460 A AT 567460A AT 217045 B AT217045 B AT 217045B
- Authority
- AT
- Austria
- Prior art keywords
- azepines
- dibenzo
- acid
- derivatives
- new
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 6
- LCGTWRLJTMHIQZ-UHFFFAOYSA-N 5H-dibenzo[b,f]azepine Chemical class C1=CC2=CC=CC=C2NC2=CC=CC=C21 LCGTWRLJTMHIQZ-UHFFFAOYSA-N 0.000 title description 6
- 238000002360 preparation method Methods 0.000 title description 5
- ZSMRRZONCYIFNB-UHFFFAOYSA-N 6,11-dihydro-5h-benzo[b][1]benzazepine Chemical class C1CC2=CC=CC=C2NC2=CC=CC=C12 ZSMRRZONCYIFNB-UHFFFAOYSA-N 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- 239000000460 chlorine Substances 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 239000007858 starting material Substances 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 239000002585 base Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- WFCSWCVEJLETKA-UHFFFAOYSA-N 2-piperazin-1-ylethanol Chemical compound OCCN1CCNCC1 WFCSWCVEJLETKA-UHFFFAOYSA-N 0.000 description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000005277 alkyl imino group Chemical group 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 150000001538 azepines Chemical class 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 2
- LIWAQLJGPBVORC-UHFFFAOYSA-N ethylmethylamine Chemical compound CCNC LIWAQLJGPBVORC-UHFFFAOYSA-N 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- MHUXTOYYIDFXRF-UHFFFAOYSA-N 2-chloro-6,11-dihydro-5h-benzo[b][1]benzazepine Chemical group C1CC2=CC=CC=C2NC2=CC(Cl)=CC=C21 MHUXTOYYIDFXRF-UHFFFAOYSA-N 0.000 description 1
- IFRKEAUJMRIYNC-UHFFFAOYSA-N 2-piperazin-1-ylethyl acetate Chemical compound CC(=O)OCCN1CCNCC1 IFRKEAUJMRIYNC-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- MFESCIUQSIBMSM-UHFFFAOYSA-N I-BCP Chemical compound ClCCCBr MFESCIUQSIBMSM-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 230000002908 adrenolytic effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001339 alkali metal compounds Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000003868 ammonium compounds Chemical group 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000002005 ganglioplegic effect Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- -1 inorganic acid halides Chemical class 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
<Desc/Clms Page number 1>
Verfahren zur Herstellung von neuen monoalkylierten bzw. monohalogenierten N-Derivaten von 10, 11-Dihydro-5H-dibenzo[b, f]azepinen und 5H-Dibenzo [b, f] azepinen
Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung von neuen, in einem aromatischen Ring monoalkylierten bzw. monohalogenierten N-Derivaten von 1O, 1l-Dihydro-5H-dibenzo[b, f]azepinen und 5H-Dibenzo- [b, f] azepinen, die wertvolle pharmakologische Eigenschaften, insbesondere antiallergische, sedative, spasmolytische, serotoninantagonistische, antiemetische und adrenolytische Wirksamkeit, besitzen und der allgemeinen Formel I :
EMI1.1
entsprechen, worin X die Äthylen- oder Vinylengruppe -CH2-CH2- bzw. -CH = CH-, Y einen Alkylenrest mit 2-6 Kohlenstoffatomen, wovon 2-4 in der direkten Kette zwischen N und Am sind, Am eine niedermolekulare Dialkylaminogruppe und R einen Alkylrest mit 2-4 Kohlenstoffatomen, ein Chlor- oder Bromatombedeuten, wobei einer derbeidenAlkylrestevonAmdirekt (l) mitdemAlkylenrestvonY oder beide Alkylreste unter sich direkt (2) oder über ein Sauerstoffatom (3), eine Alkylimino- (4), Hydroxyalkylimino- (5) oder Alkanoyloxyalkyliminogruppe (6) verbunden sein können. Diese Verbindungen der Formel I hemmen z. B. auch die durch Pilocarpin hervorgerufene Speichelsekretion.
Die genannten Stoffe kommen u. a. bei peroraler und gegebenenfalls auch subcutaner Verabreichung zur Behandlung von gewissen Formen von Geisteskrankheiten, insbesondere Gemütsdepressionen, zur Behandlung der allergischen Rhinitis sowie zur Potenzierung der Wirkung anderer Arzneistoffe, insbesondere von Nar- kotica, in Betracht.
Die folgenden Formeln sind spezielle Beispiele zur Erläuterung der oben erwähnten 6 Bindungsmöglichkeiten in der Gruppierung Y-Am :
EMI1.2
Quaternäre Ammoniumsalze, die sich von den vorstehend definierten tertiären Basen ableiten, wirken als Ganglioplegica.
<Desc/Clms Page number 2>
Zur Herstellung der neuen Verbindungen setzt man einen reaktionsfähigen Ester einer Verbindung der allgemeinen Formel II :
EMI2.1
EMI2.2
dären Amin der allgemeinen Formel III :
Am-H (111) um, wobei R, X, Y und Am die oben angegebene Bedeutung haben, jedoch naturgemäss keine Verbindung zwischen einem Alkylrest von Am und Y vorliegen kann, und führt die so erhaltene Base gegebenenfalls in ihre Salze mit anorganischen oder organischen Säuren oder durch Anlagerung eines reaktionsfähigen Esters eines aliphatischen oder araliphatischen Alkohols in eine quaternäre Ammoniumverbindung über.
Die Umsetzung kann beispielsweise bei mässig hoher Temperatur von z. B. 80 bis 120 C in einem inerten Lösungsmittel, wie z. B. einem niedermolekularen Alkanol, oder Alkanon erfolgen, wobei zweckmässig ein Überschuss des umzusetzenden Amins als säurebindendes Mittel verwendet wird. Je nach dem Siedepunkt des verwendeten Amins und des Lösungsmittels sowie der benötigten Reaktionstemperatur ist die Umsetzung gegebenenfalls im geschlossenen Gefäss durchzuführen.
Zu reaktionsfähigen Estern von Verbindungen der allgemeinen Formel II gelangt man beispielsweise durch Umsetzung von Alkalimetallverbindungen von Iminodibenzyl- bzw. Iminostilbenverbindungen der allgemeinen Formel IV :
EMI2.3
mit Alkylenoxyden und Umsetzung der erhaltenen Hydroxyalkylderivate mit anorganischen Säurehalogeniden, Methansulfonsäurechlorid oder Arylsulfonsäurechloriden, wobei 5-Halogenalkyl-iminodibenzyle, 5-Methansulfonyloxy-iminodibenzyle, 5-Arylsulfonyloxyalkyliminodibenzyle bzw. die entsprechenden Iminostilbenderivate erhalten werden. Diese können beispielsweise mit Dimethylamin, Methyläthylamin, Diäthylamin, Pyrrolidin, Piperidin, Morpholin, N-Methylpiperazin, N-Hydroxyäthyl-piperazin oder N-Acetoxyäthyl-piperazin umgesetzt werden.
Durch Anlagerung von reaktionsfähigen Estern, insbesondere Halogeniden oder Sulfaten aliphatischer oder araliphatischer Alkohole, z. B. von Methyljodid, Dimethylsulfat, Äthylbromid, Äthyljodid oder Benzylchlorid, entstehen aus den tertiären Aminen der allgemeinen Formel I in üblicher Weise monoquaternäre Ammoniumverbindungen, wobei die Gruppe Am reagiert.
Mit anorganischen oder organischen Säuren, wie Salzsäure, Bromwasserstoffsäure, Schwefelsäure, Phosphorsäure, Methansulfonsäure, Äthandisulfonsäure, Essigsäure, Citronensäure, Äpfelsäure, Bernsteinsäure, Fumarsäure, Maleinsäure, Weinsäure, Benzoesäure und Phthalsäure bilden die tertiären Basen Salze, welche zum Teil wasserlöslich sind.
Die nachfolgenden Beispiele sollen die Herstellung der neuen Verbindungen näher erläutern. Teile bedeuten darin Gewichtsteile, diese verhalten sich zu Volumteilen wie g zu cm3. Die Temperaturen sind in Celsiusgraden angegeben.
Beispiel 1 : Eine Lösung von 15 Teilen 3-Äthyl-5- (ss-chlor-äthyl)-iminodibenzyl in 100 Vol-Teilen abs. Benzol wird mit 8 Teilen Pyrrolidin versetzt und 12 Stunden am Rückfluss gekocht. Nach dem Abkühlen wird die benzolische Lösung gründlich mit Wasser gewaschen, getrocknet und eingedampft. Zum Rückstand gibt man die berechnete Menge abs. alkoholische Salzsäure, wobei das Hydrochlorid des 3- Äthyl-5- (ss-pyrrolidino-äthyl)-iminodibenzyls auskristallisiert. Es kann wie in Beispiel 1 angegeben umkristallisiert werden und schmilzt dann bei 156-158 o.
Beispiel 2 : 23 Teile 3-Chlor-iminodibenzyl und 15 Teile l-Chlor-3-brompropan werden in 200 Vol.- Teilen abs. Benzol gelöst. 4, 3 Teile Natriumamid werden in Toluol pulverisiert und die erhaltene Suspension wird bei 500 langsam unter Rühren zugetropft, worauf während 15 Stunden bei 50-600 weitergerührt wird. Das erhaltene Reaktionsgemisch wird auf Wasser gegossen, die Benzolschicht abgetrennt und mit Natriumsulfat getrocknet. Nach dem Einengen erhält man das 3-Chlor-5- (Y-Chlorpropyl)-iminodibenzyl als dunkles Öl, das direkt weiterverarbeitet werden kann.
23 Teile des oben erhaltenen Produktes werden in 150 Vol-Teilen Methyläthylketon gelöst und nach
Zusatz von 10 Teilen Natriumiodid und 13 Teilen N-Methyl-piperazin 16 Stunden unter Kochen am Rück- fluss gerührt. Das Reaktionsgemisch wird eingeengt, der Rückstand in Äther aufgenommen und die basi- schen Anteile mit verdünnter Salzsäure aus der ätherischen Lösung extrahiert. Die sauren Auszüge werden
<Desc/Clms Page number 3>
alkalisch gestellt und die ausgeschiedene Base wird in Äther aufgenommen. Nach dem Trocknen und Eindampfen der Lösung erhält man das gewünschte 3-Chlor-5-[y-N'-methyl-piperazino) -propyl]-imino- dibenzyl als Öl.
Analog wird z. B. unter Verwendung von N-Hydroxyäthyl-piperazin an Stelle von N-Methyl-piperazin das 3-Chlor-5- [Y-N'-hydroxyäthyl-piperazino)-propyl]-iminodibenzyl erhalten.
PATENTANSPRÜCHE :
1. Verfahren zur Herstellung von neuen, in einem aromatischen Ring monoalkylierten bzw. monohalogenierten N-Derivaten von 1O, 1l-Dihydro-5H-dibenzo[b, f]azepinen und 5H-Dibenzo- [b, f] azepinen der allgemeinen Formel I :
EMI3.1
worin X die Äthylen- oder Vinylengruppe -CH2-CH2- bzw. -CH = CH-, Y einen Alkylenrest mit 2-6 Kohlenstoffatomen, wovon 2-4 in der direkten Kette zwischen N und Am sind, Am eine niedermolekulare Dialkylaminogruppe und R einen Alkylrest mit 2-4 Kohlenstoffatomen, ein Chlor- oder Bromatom bedeuten, wobei einer der beiden Alkylreste von Am direkt mit dem Alkylenrest Y, oder beide Alkylreste unter sich direkt oder über ein Sauerstoffatom, eine Alkylimino-, Hydroxyalkylimino- oder Alkanoyl- oxyalkyliminogruppe verbunden sein können sowie von deren Salzen oder quaternären Ammoniumverbindungen, dadurch gekennzeichnet, dass man einen reaktionsfähigen Ester einer Verbindung der allgemeinen Formel II :
EMI3.2
mit einem sekundären Amin der allgemeinen Formel III :
Am-H (111) umsetzt, wobei R, X, Y und Am die oben angegebene Bedeutung haben, jedoch naturgemäss keine Verbindung zwischen einem Alkylrest von Am und Y vorliegen kann, und die so erhaltene Base gegebenenfalls in ihre Salze mit anorganischen oder organischen Säuren, oder durch Anlagerung eines reaktionsfähigen Esters eines aliphatischen oder araliphatischen Alkohols in eine quaternäre Ammoniumverbindung überführt.
<Desc / Clms Page number 1>
Process for the preparation of new monoalkylated or monohalogenated N-derivatives of 10, 11-dihydro-5H-dibenzo [b, f] azepines and 5H-dibenzo [b, f] azepines
The present invention relates to a process for the preparation of new, in an aromatic ring monoalkylated or monohalogenated N-derivatives of 1O, 1l-dihydro-5H-dibenzo [b, f] azepines and 5H-dibenzo- [b, f] azepines, which have valuable pharmacological properties, in particular antiallergic, sedative, spasmolytic, serotonin-antagonistic, antiemetic and adrenolytic activity, and the general formula I:
EMI1.1
where X is the ethylene or vinylene group -CH2-CH2- or -CH = CH-, Y is an alkylene radical with 2-6 carbon atoms, of which 2-4 are in the direct chain between N and Am, Am is a low molecular weight dialkylamino group and R is an alkyl radical with 2-4 carbon atoms, a chlorine or bromine atom, where one of the two alkyl radicals of Am directly (1) with the alkylene radical of Y or both alkyl radicals directly (2) or via an oxygen atom (3), an alkylimino (4), hydroxyalkylimino (5 ) or alkanoyloxyalkylimino group (6) may be linked. These compounds of formula I inhibit z. B. also the saliva secretion caused by pilocarpine.
The substances mentioned come u. a. in the case of peroral and optionally also subcutaneous administration for the treatment of certain forms of mental illnesses, in particular mood depressions, for the treatment of allergic rhinitis and for potentiating the action of other medicinal substances, in particular narcotics.
The following formulas are specific examples to explain the above-mentioned 6 bonding possibilities in the group Y-Am:
EMI1.2
Quaternary ammonium salts derived from the tertiary bases defined above act as ganglioplegics.
<Desc / Clms Page number 2>
To prepare the new compounds, a reactive ester of a compound of the general formula II is used:
EMI2.1
EMI2.2
the amine of the general formula III:
Am-H (111) um, where R, X, Y and Am have the meanings given above, but naturally there cannot be a connection between an alkyl radical of Am and Y, and converts the base obtained in this way into its salts with inorganic or organic Acids or by addition of a reactive ester of an aliphatic or araliphatic alcohol into a quaternary ammonium compound.
The reaction can, for example, at a moderately high temperature of, for. B. 80 to 120 C in an inert solvent, such as. B. a low molecular weight alkanol, or alkanone, it is expedient to use an excess of the amine to be reacted as the acid-binding agent. Depending on the boiling point of the amine and the solvent used and the required reaction temperature, the reaction may have to be carried out in a closed vessel.
Reactive esters of compounds of general formula II are obtained, for example, by reacting alkali metal compounds of iminodibenzyl or iminostilbene compounds of general formula IV:
EMI2.3
with alkylene oxides and reaction of the hydroxyalkyl derivatives obtained with inorganic acid halides, methanesulfonic acid chloride or arylsulfonic acid chlorides, 5-haloalkyl-iminodibenzyls, 5-methanesulfonyloxy-iminodibenzyls, 5-arylsulfonyloxyalkyliminodibenzyls or the corresponding iminostilbene derivatives being obtained. These can be reacted, for example, with dimethylamine, methylethylamine, diethylamine, pyrrolidine, piperidine, morpholine, N-methylpiperazine, N-hydroxyethyl piperazine or N-acetoxyethyl piperazine.
By addition of reactive esters, especially halides or sulfates of aliphatic or araliphatic alcohols, e.g. B. of methyl iodide, dimethyl sulfate, ethyl bromide, ethyl iodide or benzyl chloride arise from the tertiary amines of the general formula I in the usual way monoquaternary ammonium compounds, the group Am reacting.
With inorganic or organic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethane disulfonic acid, acetic acid, citric acid, malic acid, succinic acid, fumaric acid, maleic acid, tartaric acid, benzoic acid and phthalic acid, the tertiary bases form salts, some of which are water-soluble.
The following examples are intended to explain the preparation of the new compounds in more detail. Parts mean parts by weight; these relate to parts by volume as g to cm3. The temperatures are given in degrees Celsius.
Example 1: A solution of 15 parts of 3-ethyl-5- (ss-chloro-ethyl) -iminodibenzyl in 100 parts by volume of abs. Benzene is mixed with 8 parts of pyrrolidine and refluxed for 12 hours. After cooling, the benzene solution is washed thoroughly with water, dried and evaporated. The calculated amount of abs is added to the residue. alcoholic hydrochloric acid, the hydrochloride of 3-ethyl-5- (ss-pyrrolidino-ethyl) -iminodibenzyl crystallizes out. It can be recrystallized as indicated in Example 1 and then melts at 156-158 o.
Example 2: 23 parts of 3-chloro-iminodibenzyl and 15 parts of l-chloro-3-bromopropane are dissolved in 200 parts by volume of abs. Benzene dissolved. 4.3 parts of sodium amide are pulverized in toluene and the suspension obtained is slowly added dropwise at 500 ° with stirring, whereupon stirring is continued for 15 hours at 50-600. The reaction mixture obtained is poured into water, the benzene layer is separated off and dried with sodium sulfate. After concentration, the 3-chloro-5- (Y-chloropropyl) -iminodibenzyl is obtained as a dark oil, which can be further processed directly.
23 parts of the product obtained above are dissolved in 150 parts by volume of methyl ethyl ketone and after
Addition of 10 parts of sodium iodide and 13 parts of N-methylpiperazine, stirred under reflux for 16 hours. The reaction mixture is concentrated, the residue is taken up in ether and the basic components are extracted from the ethereal solution with dilute hydrochloric acid. The sour extracts will be
<Desc / Clms Page number 3>
made alkaline and the precipitated base is taken up in ether. After drying and evaporation of the solution, the desired 3-chloro-5- [γ-N'-methyl-piperazino) propyl] -imino-dibenzyl is obtained as an oil.
Analog is z. B. using N-hydroxyethyl-piperazine instead of N-methyl-piperazine to obtain 3-chloro-5- [Y-N'-hydroxyethyl-piperazino) propyl] -iminodibenzyl.
PATENT CLAIMS:
1. Process for the preparation of new, in an aromatic ring monoalkylated or monohalogenated N-derivatives of 1O, 1l-dihydro-5H-dibenzo [b, f] azepines and 5H-dibenzo- [b, f] azepines of the general formula I :
EMI3.1
where X is the ethylene or vinylene group -CH2-CH2- or -CH = CH-, Y is an alkylene radical with 2-6 carbon atoms, of which 2-4 are in the direct chain between N and Am, Am is a low molecular weight dialkylamino group and R is one Alkyl radical with 2-4 carbon atoms, a chlorine or bromine atom, where one of the two alkyl radicals of Am directly with the alkylene radical Y, or both alkyl radicals directly or via an oxygen atom, an alkylimino, hydroxyalkylimino or alkanoyl oxyalkylimino group can as well as their salts or quaternary ammonium compounds, characterized in that a reactive ester of a compound of the general formula II:
EMI3.2
with a secondary amine of the general formula III:
Am-H (111), where R, X, Y and Am have the meanings given above, but naturally no connection between an alkyl radical of Am and Y can be present, and the base thus obtained, if appropriate, into its salts with inorganic or organic acids , or converted into a quaternary ammonium compound by addition of a reactive ester of an aliphatic or araliphatic alcohol.
Claims (1)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH217045X | 1958-12-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AT217045B true AT217045B (en) | 1961-09-11 |
Family
ID=4449913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT567460A AT217045B (en) | 1958-12-06 | 1959-12-05 | Process for the preparation of new monoalkylated or monohalogenated N-derivatives of 10,11-dihydro-5H-dibenzo [b, f] azepines and 5H-dibenzo [b, f] azepines |
Country Status (1)
| Country | Link |
|---|---|
| AT (1) | AT217045B (en) |
-
1959
- 1959-12-05 AT AT567460A patent/AT217045B/en active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE1620022A1 (en) | New 1-aminofluorenone derivatives and processes for their preparation | |
| DE2426149B2 (en) | 7-Fluoro-substituted phenothiazines, processes for their preparation and pharmaceutical compositions containing them | |
| DE1237574B (en) | Process for the preparation of piperazine derivatives | |
| AT200578B (en) | Process for the preparation of new N-aminoalkyl derivatives of azepines | |
| AT217045B (en) | Process for the preparation of new monoalkylated or monohalogenated N-derivatives of 10,11-dihydro-5H-dibenzo [b, f] azepines and 5H-dibenzo [b, f] azepines | |
| DE1493855C3 (en) | 1-square bracket to p- (dialkylaminoalkoxy) -phenyl square bracket to -i-phenyl-2-phenyl-n-alkane and process for their preparation | |
| DE1076691B (en) | Process for the preparation of phenthiazine derivatives | |
| DE1468138B2 (en) | PROCESS FOR PREPARING 10,11-DIHYDRO-DIBENZO SQUARE BRACKET TO A,D SQUARE BRACKET TO -CYCLOHEPTENES | |
| AT220624B (en) | Process for the preparation of new N-heterocyclic compounds | |
| AT208869B (en) | Process for the production of new N-substituted azepines | |
| AT233013B (en) | Process for the preparation of new iminodibenzyl derivatives | |
| AT208870B (en) | Process for the production of new N-substituted azepines or dihydroazepines | |
| AT233579B (en) | Process for the preparation of new iminodibenzyl derivatives | |
| AT219613B (en) | Process for the preparation of new N-heterocyclic compounds and their salts | |
| AT219612B (en) | Process for the preparation of new N-heterocyclic compounds and their salts | |
| AT222130B (en) | Process for the preparation of new N-heterocyclic compounds | |
| AT222658B (en) | Process for the preparation of new derivatives of substituted 5H-dibenzo [b, f] azepines | |
| DE1161278B (en) | Process for the production of azepine derivatives and their salts. | |
| AT214935B (en) | Process for the preparation of new N-derivatives of 10,11-dihydro-5-benzo [b, f] azepines and 5-dibenzo [b, f] -azepines | |
| AT217046B (en) | Process for the preparation of new monoalkylated or monohalogenated N-derivatives of 10,11-dihydro-5H-dibenzo [b, f] azepines and 5H-dibenzo [b, f] azepines | |
| DE1192211B (en) | Process for the preparation of basic substituted iminostilbenes and their salts | |
| AT208871B (en) | Process for the production of new N-substituted azepines or dihydroazepines | |
| AT228790B (en) | Process for the preparation of new 9-aminopropylidene-9,10-dihydroanthracenes and their acid addition salts | |
| AT217044B (en) | Process for the preparation of new monoalkylated or monohalogenated N-derivatives of 10,11-dihydro-5 H-dibenzo [b, f] azepines and 5 H-dibenzo [b, f] azepines | |
| AT233019B (en) | Process for the preparation of new iminodibenzyl derivatives |